Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 16 , ISSUE 3 ( July, 2012 ) > List of Articles

RESEARCH ARTICLE

Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia

Fanak Fahimi, Hamidreza Jamaati, Seyed Mohammad Hashemian, Arvin Najafi, Somayeh Ghafari, Payam Tabarsi, Arnavaz Akhzarmehr

Keywords : Piperacillin, tazobactam, ventilator-associated pneumonia

Citation Information : Fahimi F, Jamaati H, Hashemian SM, Najafi A, Ghafari S, Tabarsi P, Akhzarmehr A. Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. Indian J Crit Care Med 2012; 16 (3):141-147.

DOI: 10.4103/0972-5229.102083

License: CC BY-ND 3.0

Published Online: 01-07-2012

Copyright Statement:  Copyright © 2012; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and Aims: Ventilator-associated pneumonia (VAP) is one of the most common Intensive Care Unit (ICU)-acquired infection. The aim of this study was to compare the clinical outcome of continuous and intermittent administration of piperacillin-tazobactam by serial measurements of the Clinical Pulmonary Infection Score (CPIS). Subjects and Methods: Groups were designed as parallel and the study was designed as quasi-experimental and conducted at a semi-closed ICU between September 2008 and May 2010. Patients received 3.375 g (piperacillin 3 g/tazobactam 0.375 g) either through intermittent infusion every 6 h for 30 min [Intermittent Infusion (II) group; n = 30] or through continuous infusion every 8 h for 4 h [Continuous Infusion (CI) group; n = 31]. CPIS was used to assess the clinical diagnosis and outcome of VAP patients. Results: Sex, age, Acute Physiology and Chronic Health Evaluation II II score on ICU admission, diagnosis and underlying disease of VAP patients were not significantly different in the CI (n = 31) and II (n = 30) groups. Duration of mechanical ventilation, length of stay, total number of antibiotics used per patient and duration of piperacillin/tazobactam treatment were similar in both groups. Mortality rates of VAP patients were similar between both groups during hospitalization. Conclusion: There was no significant difference in clinical outcomes of patients receiving piperacillin-tazobactam via CI or II when measured by serial CPIS score.


PDF Share
  1. Ventilator-associated pneumonia. Eur J Intern Med 2010;21:360-8.
  2. Ventilator-associated pneumonia: Clinical considerations. AJR Am J Roentgenol 1994;163:1031-5.
  3. The incidence and risk factors of ventilator-associated pneumonia in a Riyadh hospital. Infect Control Hosp Epidemiol 2000;21:271-3.
  4. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
  5. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10; quiz 11-2.
  6. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998;27:10-22.
  7. Beta-lactam antibiotics: Is continuous infusion the preferred method of administration? Ann Pharmacother 1995;29:415-24.
  8. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000;50:184-91.
  9. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin]. Pathol Biol (Paris) 2001;49:540-7.
  10. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001;17:497-504.
  11. Cefepime in critically ill patients: Continuous infusion vs. an intermittent dosing regimen. Int J Clin Pharmacol Ther 2005;43:360-9.
  12. [A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time]. Jpn J Antibiot 2005;58:452-7.
  13. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-61.
  14. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7.
  15. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? J Antimicrob Chemother 2007;59:285-91.
  16. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-10.
  17. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000;179:436-40.
  18. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002;22:471-83.
  19. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001;21:549-55.
  20. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009;33:464-8.
  21. Pharmacokinetics of piperacillin-tazobactam: Intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005;25:62-7.
  22. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-9.
  23. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
  24. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9.
  25. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
  26. Once-daily aminoglycosides. Conn Med 1992;56:561-3. Erratum in: Conn Med 1992;56:694.
  27. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009;64:236-40.
  28. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791-9.
  29. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988;138:110-6.
  30. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. Chest 1992;101:458-63.
  31. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am Rev Respir Dis 1987;135:426-32.
  32. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371-5.
  33. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676-82.
  34. The diagnosis of pneumonia in the critically ill. Chest 1995;108 (2 Suppl):17S-25S.
  35. Leukocytosis: Basics of clinical assessment. Am Fam Physician 2000;62:2053-60.
  36. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
  37. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989;139:877-84.
  38. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995;108:1655-62.
  39. Incidence, risk, and prognostic factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990;142:523-8.
  40. Predominant pathogens found in the European prevalence of infection in intensive care study. Eur J Clin Microbiol Infect Dis 1996;15:281-5.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.